Tokyo Tape
Sign in
← Jmdc

Quarterly report · Q3

4483.TEDINET S100Q8QG
Period2022-04-01 → 2022-12-31
Filed2023-02-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥19.5bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥7.5bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Revenue¥21.8bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥15.7bn2021-04-01 → 2021-12-31Cons.Revenue IFRS
Revenue¥6.1bn2021-10-01 → 2021-12-31dCons.Revenue IFRS
Operating income¥4.0bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥1.8bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Operating income¥3.4bn2021-04-01 → 2021-12-31Cons.Operating profit loss IFRS
Operating income¥1.7bn2021-10-01 → 2021-12-31dCons.Operating profit loss IFRS
Profit before tax¥4.0bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥1.8bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Profit before tax¥4.8bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥3.4bn2021-04-01 → 2021-12-31Cons.Profit loss before tax IFRS
Profit before tax¥1.7bn2021-10-01 → 2021-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥2.7bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.2bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥3.2bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥2.3bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.1bn2021-10-01 → 2021-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥2.7bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥1.2bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Net income¥2.3bn2021-04-01 → 2021-12-31Cons.Profit loss IFRS
Net income¥1.1bn2021-10-01 → 2021-12-31dCons.Profit loss IFRS
Total assets¥95.1bnat 2022-12-31Cons.Assets IFRS
Total assets¥62.1bnat 2022-03-31Cons.Assets IFRS
Total assets¥60.4bnat 2021-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥32.3bnat 2022-12-31Cons.Liabilities IFRS
Total liabilities¥30.9bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥62.9bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥31.2bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥30.1bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥28.3bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥62.9bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥31.2bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥30.1bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥21.8bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥13.2bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.5bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥19.9bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥2.5bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥3.8bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥1.9bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥21.8bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥8.1bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥5.3bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥27.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥2.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥2.1bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥44.982022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥19.282022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥57.742021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥40.462021-04-01 → 2021-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥20.162021-10-01 → 2021-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥42.662022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥18.452022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥54.162021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥38.142021-04-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥18.992021-10-01 → 2021-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio66.1%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio50.2%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio49.9%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 72
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥189m
Reconciling Itemsreconcilingrevenue2022-10-01 → 2022-12-31−¥62m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥189m
Reconciling Itemsreconcilingrevenue intersegment2022-10-01 → 2022-12-31−¥62m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥417m
Reconciling Itemsreconcilingsegment profit2022-10-01 → 2022-12-31−¥227m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-04-01 → 2022-12-31¥2.8bn
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-10-01 → 2022-12-31¥944m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-04-01 → 2022-12-31¥2.7bn
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-10-01 → 2022-12-31¥901m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥127m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥43m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-04-01 → 2022-12-31¥310m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-10-01 → 2022-12-31¥118m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue2022-04-01 → 2022-12-31¥13.1bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue2022-10-01 → 2022-12-31¥5.2bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-04-01 → 2022-12-31¥13.1bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-10-01 → 2022-12-31¥5.2bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥62m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥19m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-04-01 → 2022-12-31¥4.0bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-10-01 → 2022-12-31¥2.0bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue2022-04-01 → 2022-12-31¥3.8bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue2022-10-01 → 2022-12-31¥1.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue external2022-04-01 → 2022-12-31¥3.8bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue external2022-10-01 → 2022-12-31¥1.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentsegment profit2022-04-01 → 2022-12-31¥1.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentsegment profit2022-10-01 → 2022-12-31¥492m
—segment totalrevenue2022-04-01 → 2022-12-31¥19.7bn
—segment totalrevenue2022-10-01 → 2022-12-31¥7.5bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥19.5bn
—segment totalrevenue external2022-10-01 → 2022-12-31¥7.5bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥189m
—segment totalrevenue intersegment2022-10-01 → 2022-12-31¥62m
—segment totalsegment profit2022-04-01 → 2022-12-31¥5.7bn
—segment totalsegment profit2022-10-01 → 2022-12-31¥2.6bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥143m
Reconciling Itemsreconcilingrevenue2021-10-01 → 2021-12-31−¥54m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥143m
Reconciling Itemsreconcilingrevenue intersegment2021-10-01 → 2021-12-31−¥54m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥242m
Reconciling Itemsreconcilingsegment profit2021-10-01 → 2021-12-31−¥85m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2021-04-01 → 2021-12-31¥2.6bn
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2021-10-01 → 2021-12-31¥907m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2021-04-01 → 2021-12-31¥2.5bn
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2021-10-01 → 2021-12-31¥873m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥90m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥34m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2021-04-01 → 2021-12-31¥209m
jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2021-10-01 → 2021-12-31¥46m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue2021-04-01 → 2021-12-31¥9.9bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue2021-10-01 → 2021-12-31¥4.1bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue external2021-04-01 → 2021-12-31¥9.8bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue external2021-10-01 → 2021-12-31¥4.0bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥52m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2021-10-01 → 2021-12-31¥20m
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentsegment profit2021-04-01 → 2021-12-31¥3.4bn
jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segmentsegment profit2021-10-01 → 2021-12-31¥1.7bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue2021-04-01 → 2021-12-31¥3.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue2021-10-01 → 2021-12-31¥1.2bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue external2021-04-01 → 2021-12-31¥3.4bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentrevenue external2021-10-01 → 2021-12-31¥1.2bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentsegment profit2021-04-01 → 2021-12-31¥1.2bn
jpcrp040300-q3r_E35308-000Tele Medicinereportable segmentsegment profit2021-10-01 → 2021-12-31¥470m
—segment totalrevenue2021-04-01 → 2021-12-31¥15.8bn
—segment totalrevenue2021-10-01 → 2021-12-31¥6.2bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥15.7bn
—segment totalrevenue external2021-10-01 → 2021-12-31¥6.1bn
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥143m
—segment totalrevenue intersegment2021-10-01 → 2021-12-31¥54m
—segment totalsegment profit2021-04-01 → 2021-12-31¥4.8bn
—segment totalsegment profit2021-10-01 → 2021-12-31¥2.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 842
ItemContextValueUnit
Equity IFRSPrior1YearInstant_CapitalSurplusIFRSMember12483000000JPY
Equity IFRSPrior1YearInstant_TreasurySharesIFRSMember-2000000JPY
Equity IFRSPrior1YearInstant_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-4000000JPY
Equity IFRSPrior1YearInstant_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Equity IFRSPrior1YearInstant_ShareAcquisitionRightsIFRSMember21000000JPY
Profit loss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember0JPY
Other comprehensive income IFRSCurrentYTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember3000000JPY
Other comprehensive income IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember－JPY
Comprehensive income IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Comprehensive income IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Comprehensive income IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Comprehensive income IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember0JPY
Comprehensive income IFRSCurrentYTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember3000000JPY
Comprehensive income IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember－JPY
Issuance of share acquisition rights ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Issuance of share acquisition rights ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Issuance of share acquisition rights ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Issuance of share acquisition rights ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Issuance of share acquisition rights ss IFRSCurrentYTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Issuance of share acquisition rights ss IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember13000000JPY
Exercise of share acquisition rights ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember155000000JPY
Exercise of share acquisition rights ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember155000000JPY
Exercise of share acquisition rights ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Exercise of share acquisition rights ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Exercise of share acquisition rights ss IFRSCurrentYTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Exercise of share acquisition rights ss IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember-1000000JPY
Forfeiture of share acquisition rights ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Forfeiture of share acquisition rights ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember0JPY
Forfeiture of share acquisition rights ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Forfeiture of share acquisition rights ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Forfeiture of share acquisition rights ss IFRSCurrentYTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Forfeiture of share acquisition rights ss IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember-0JPY
Issuance of new shares ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember14732000000JPY
Issuance of new shares ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember14558000000JPY
Issuance of new shares ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Issuance of new shares ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Issuance of new shares ss IFRSCurrentYTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Issuance of new shares ss IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember－JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Purchase of treasury shares ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember-0JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2021-10-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass